Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA
Citations 1
PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1758-1759